On the evening of January 6, 2025, Qingdao Haier Biomedical Co., Ltd. ("Haier Bio", 688139.SH) and Shanghai Laishi Blood Products Co., Ltd. ("Shanghai Laishi", 002252.SZ) announced the termination of the planning for a major asset restructuring and the resumption of the company's stock trading. They have decided to terminate the substantial asset restructuring plan for Haier Bio to absorb and merge with Shanghai Laishi. At the same time, both companies issued announcements regarding a proposal from the chairman to repurchase shares. Haier Bio's share repurchase plan totals between 100 million to 200 million yuan, while Shanghai Laishi's totals between 250 million to 500 million yuan. The stocks of both companies will resume trading at the opening on Tuesday, January 7, 2025.

According to the announcements from both companies, to enhance investor confidence and based on strong confidence in the future development of Haier Bio and Shanghai Laishi, as well as a high recognition of their company values, the chairman has proposed the share repurchase. The repurchased shares will be fully utilized for employee stock ownership plans or equity incentives at a suitable time in the future, with both companies funding the repurchases from their own resources.

It is understood that on June 18, 2024, Shanghai Laishi was officially integrated into Haier's health sector "Yingkang Yisheng", focusing on blood product businesses, promoting strategies to "expand plasma" and "defat plasma", and expanding into blood-derived pharmaceuticals and non-blood innovation drugs. At the same time, Shanghai Laishi insists on driving innovation through technology and will conduct in-depth cooperation with Haier Bio in the upstream and downstream of the blood industry chain, including comprehensive solutions for pharmaceutical multiple scenes and the digital upgrade of the blood industry chain, in order to fully implement the national "three-year action plan for intelligent supervision of blood product production" and gradually grow into a comprehensive biopharmaceutical enterprise.

Haier Bio, which landed on the STAR Market in 2019, is the first listed company incubated under the "Yingkang Yisheng" innovation strategy, primarily focusing on the life sciences field, building a digital scene ecosystem that combines life sciences and medical innovation, and providing comprehensive digital solutions for biopharmaceuticals, university research, hospital services, public health and disease control, and blood products. Among them, Haier Bio's smart city blood network built for Qingdao has pioneered a full-process traceability and digital management from blood collection, preparation, storage, dispatching to clinical use of blood.

Regarding the termination of this major asset restructuring planning, Yingkang Yisheng stated: Due to the complex structure of this transaction, a specific plan recognized by all relevant parties has not yet been formed. After careful consideration of the opinions of relevant parties and mutual agreement through negotiations, Haier Bio and Shanghai Laishi decided to terminate the planning of this major asset restructuring, in order to effectively safeguard the interests of the listed company and the vast number of investors. This decision will not affect the normal business operations of either company nor the interests of the companies' shareholders, especially small and medium shareholders.

"Haier Bio and Shanghai Laishi are both under Haier's health sector 'Yingkang Yisheng'. Not only are they highly coordinated along the industrial chain, but they will continue to deepen cooperation and delve into the biotechnology industry under the vision of 'a lifetime of wellness for everyone'," stated Yingkang Yisheng.

https://finance.eastmoney.com/a/202501063288918245.html